Corcept Therapeutics Incorporated (CORT) Ownership
CORT ownership summary
as of October 18, 2026- Institutions
- 77.0% of shares outstanding
- Insiders
- 11.46% of shares outstanding
- Shares outstanding
- 108.1M
- Float
- 96.5M shares available to trade
- Short interest
- 10.18% 8.5M shares short
- Days to cover
- 5.11 short interest down 8.7% vs prior month
- Institutions 76.96%
- Insiders 11.46%
- Other investors 11.57%
CORT top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | BlackRock Inc | 11.50% | 12.4M | $1.37B | +280,747 (+2.3%) | June 30, 2026 |
| 2 | Ingalls & Snyder LLC | 7.34% | 7.9M | $874.1M | +325,791 (+4.3%) | June 30, 2026 |
| 3 | Renaissance Technologies Corp | 4.87% | 5.3M | $579.6M | −421,155 (−7.4%) | June 30, 2026 |
| 4 | Vanguard Portfolio Management, LLC | 4.67% | 5.0M | $555.7M | +224,070 (+4.6%) | June 30, 2026 |
| 5 | Vanguard Capital Management, LLC | 3.86% | 4.2M | $459.6M | +95,286 (+2.3%) | June 30, 2026 |
| 6 | Parallel Advisors, LLC | 3.67% | 4.0M | $436.5M | −15,227 (−0.4%) | June 30, 2026 |
| 7 | FMR Inc | 3.09% | 3.3M | $367.7M | +147,426 (+4.6%) | June 30, 2026 |
| 8 | State Street Corp | 3.03% | 3.3M | $361.3M | +78,435 (+2.5%) | June 30, 2026 |
| 9 | AQR Capital Management LLC | 2.39% | 2.6M | $284.5M | +2.2M (+535.8%) | June 30, 2026 |
| 10 | Geode Capital Management, LLC | 2.34% | 2.5M | $278.9M | −181,321 (−6.7%) | June 30, 2026 |
| 11 | First Trust Advisors L.P. | 1.69% | 1.8M | $201.5M | −343,831 (−15.8%) | June 30, 2026 |
| 12 | TANG CAPITAL MANAGEMENT LLC | 1.39% | 1.5M | $165.2M | — | June 30, 2026 |
| 13 | UBS Group AG | 1.27% | 1.4M | $151.8M | +13,990 (+1.0%) | June 30, 2026 |
| 14 | Dimensional Fund Advisors, Inc. | 1.22% | 1.3M | $145.3M | −234,314 (−15.1%) | June 30, 2026 |
| 15 | Charles Schwab Investment Management Inc | 1.07% | 1.2M | $127.5M | +37,621 (+3.4%) | June 30, 2026 |
| 16 | Morgan Stanley - Brokerage Accounts | 1.05% | 1.1M | $125.3M | +118,714 (+11.7%) | June 30, 2026 |
| 17 | D. E. Shaw & Co LP | 0.82% | 883K | $97.3M | −298,347 (−25.3%) | June 30, 2026 |
| 18 | HPM Partners LLC | 0.74% | 797K | $87.8M | +65,430 (+8.9%) | June 30, 2026 |
| 19 | MPM Oncology Impact Management LP | 0.71% | 771K | $84.9M | −214,672 (−21.8%) | June 30, 2026 |
| 20 | Northern Trust Corp | 0.70% | 754K | $83.0M | +110,638 (+17.2%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 12 holders added 3.7M shares and 7 cut 1.7M.
CORT top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | iShares Core S&P Mid-Cap ETF | 3.13% | 3.4M | $373.3M | −1,212 (−0.0%) | September 30, 2026 |
| 2 | Vanguard MStar Total Stk Mkt Idx Invest | 2.68% | 2.9M | $319.5M | −3,391 (−0.1%) | August 31, 2026 |
| 3 | Vanguard Small Cap Index | 2.03% | 2.2M | $241.3M | +90,591 (+4.3%) | September 30, 2026 |
| 4 | Fidelity Contrafund | 1.35% | 1.5M | $161.3M | −478 (−0.0%) | August 31, 2026 |
| 5 | Vanguard MStar Small Cap Growth Indx Inv | 1.13% | 1.2M | $134.1M | +12,638 (+1.0%) | September 30, 2026 |
| 6 | First Trust NYSE Arca Biotech ETF | 0.91% | 985K | $108.5M | — | September 30, 2026 |
| 7 | State Street® SPDR® S&P MIDCAP 400® ETF | 0.65% | 703K | $77.5M | +703,363 (0.0%) | September 30, 2026 |
| 8 | iShares S&P Mid-Cap 400 Growth ETF | 0.51% | 549K | $60.5M | −586 (−0.1%) | September 30, 2026 |
| 9 | iShares Russell Mid-Cap Growth ETF | 0.49% | 533K | $58.8M | −570 (−0.1%) | September 30, 2026 |
| 10 | Fidelity Select Biotechnology | 0.47% | 507K | $55.8M | — | August 31, 2026 |
| 11 | State Street SPDR Port S&P 400 Md CpETF | 0.47% | 503K | $55.4M | −704 (−0.1%) | September 30, 2026 |
| 12 | Fidelity Extended Market Index | 0.43% | 466K | $51.3M | −5,655 (−1.2%) | August 31, 2026 |
| 13 | iShares Russell Mid-Cap ETF | 0.36% | 392K | $43.1M | +722 (+0.2%) | September 30, 2026 |
| 14 | Fidelity Mid Cap Index | 0.33% | 361K | $39.7M | +1,355 (+0.4%) | August 31, 2026 |
| 15 | iShares Russell 1000 Growth ETF | 0.33% | 356K | $39.2M | −238 (−0.1%) | September 30, 2026 |
| 16 | iShares US Pharmaceuticals ETF | 0.32% | 347K | $38.2M | +1,068 (+0.3%) | September 30, 2026 |
| 17 | Strategic Advisers Fidelity US TtlStk | 0.32% | 341K | $37.6M | +3,587 (+1.1%) | August 31, 2026 |
| 18 | Fidelity VIP Mid Cap Initial | 0.31% | 338K | $37.2M | −120,900 (−26.3%) | August 31, 2026 |
| 19 | TD Global Capital Reinvestment - I | 0.29% | 316K | $34.8M | — | December 31, 2025 |
| 20 | Fidelity Contrafund K6 | 0.29% | 314K | $34.5M | −764 (−0.2%) | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
CORT insider transactions
latest 20| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-07 | William Guyer | Sell | $40.97 | 20,000 | $819,400 |
| 2026-03-25 | Joseph K Belanoff | Sell | $50.07 | 26,198 | $1.3M |
| 2026-03-20 | William Guyer | Sell | $36.01 | 11,767 | $423,730 |
| 2026-03-17 | G Leonard Baker Jr | Buy | $33.14 | 100,000 | $3.3M |
| 2026-03-04 | William Guyer | Sell | $35.99 | 8,233 | $296,306 |
| 2026-02-03 | William Guyer | Sell | $40.87 | 20,000 | $817,400 |
| 2026-01-06 | William Guyer | Sell | $35.18 | 20,000 | $703,600 |
| 2025-12-02 | William Guyer | Sell | $80.08 | 20,000 | $1.6M |
| 2025-12-01 | Sean Maduck | Sell | $79.52 | 20,000 | $1.6M |
| 2025-12-01 | Joseph K Belanoff | Sell | $79.77 | 40,000 | $3.2M |
| 2025-12-01 | Joseph Douglas Lyon | Sell | $79.53 | 5,000 | $397,650 |
| 2025-11-25 | William Guyer | Sell | $80.90 | 4,500 | $364,050 |
| 2025-11-05 | Joseph K Belanoff | Sell | $74.77 | 28,782 | $2.2M |
| 2025-11-05 | William Guyer | Sell | $75.36 | 20,000 | $1.5M |
| 2025-11-03 | Sean Maduck | Sell | $73.99 | 20,000 | $1.5M |
| 2025-11-03 | Joseph K Belanoff | Sell | $74.08 | 11,218 | $831,029 |
| 2025-11-03 | Joseph Douglas Lyon | Sell | $73.65 | 5,000 | $368,250 |
| 2025-10-10 | Daniel N Swisher Jr | Sell | $87.54 | 2,200 | $192,588 |
| 2025-10-07 | William Guyer | Sell | $89.94 | 20,000 | $1.8M |
| 2025-10-01 | Joseph Douglas Lyon | Sell | $84.75 | 5,000 | $423,750 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
CORT shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns CORT
Institutional investors own 77.0% of Corcept Therapeutics's shares and insiders 11.46%. The largest holder is BlackRock Inc with 11.50% of the shares (12.4M), as of June 30, 2026. Among the top 20 institutions, 12 added shares and 7 reduced their stake in the latest filings. Short interest is 10.18% of the float, or 5.11 days of average trading volume. The share count rose 17.6% since 2014.
Related: CORT analyst forecast, CORT key metrics. See the CORT stock overview for the latest quote and news.
CORT ownership FAQ
Who owns the most Corcept Therapeutics stock?
The largest shareholders of Corcept Therapeutics are BlackRock Inc (11.50%), Ingalls & Snyder LLC (7.34%), Renaissance Technologies Corp (4.87%), Vanguard Portfolio Management, LLC (4.67%), Vanguard Capital Management, LLC (3.86%).
What percentage of Corcept Therapeutics is owned by institutions?
Institutions hold 77.0% of Corcept Therapeutics's shares outstanding; insiders hold 11.46%.
Which funds own Corcept Therapeutics?
The largest fund holders of Corcept Therapeutics are iShares Core S&P Mid-Cap ETF (3.13%), Vanguard MStar Total Stk Mkt Idx Invest (2.68%), Vanguard Small Cap Index (2.03%), Fidelity Contrafund (1.35%), Vanguard MStar Small Cap Growth Indx Inv (1.13%).
What is Corcept Therapeutics's short interest?
8.5M shares of Corcept Therapeutics were sold short, 10.18% of the float; at the average daily volume it would take 5.11 days to cover.
Are insiders buying or selling Corcept Therapeutics?
Of the latest 20 reported insider transactions in Corcept Therapeutics (since October 1, 2025), 1 were purchases and 19 were sales.
How many shares of Corcept Therapeutics are outstanding?
Corcept Therapeutics has 108.1M shares outstanding, of which 96.5M are in the public float.